Atacicept: targeting B cells in multiple sclerosis

Cutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL

(2014) M. J. Benson et al.   JOURNAL OF IMMUNOLOGY

Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

(2010) Jerold Chun et al.   CLINICAL NEUROPHARMACOLOGY

Environmental factors and their timing in adult-onset multiple sclerosis

(2010) Adam E. Handel et al.   Nature Reviews Neurology

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term B-Lymphocyte Depletion With Rituximab in Patients With Relapsing-Remitting Multiple Sclerosis

(2009) Olaf Stüve et al.   ARCHIVES OF NEUROLOGY

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

(2009) Volker Brinkmann   BRITISH JOURNAL OF PHARMACOLOGY

Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus

(2009) I. Nestorov et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

(2009) C Pena-Rossi et al.   LUPUS

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cells

(2008) Stamatis-Nick C. Liossis et al.   CLINICAL IMMUNOLOGY

B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data

(2008) Kathleen Hawker   CURRENT OPINION IN NEUROLOGY

B lymphocytes - chief players and therapeutic targets in autoimmune diseases

(2008) Moncef Zouali   Frontiers in Bioscience-Landmark

Pharmacokinetics and Biological Activity of Atacicept in Patients With Rheumatoid Arthritis

(2008) Ivan Nestorov et al.   JOURNAL OF CLINICAL PHARMACOLOGY

B cells and multiple sclerosis

(2008) Diego Franciotta et al.   LANCET NEUROLOGY

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nonclinical Safety, Pharmacokinetics, and Pharmacodynamics of Atacicept

(2008) Michela Carbonatto et al.   TOXICOLOGICAL SCIENCES